SRR12696773
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.400
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- GLYCOLYSIS+0.400
- HEDGEHOG_SIGNALING+0.400
- HYPOXIA+0.400
- MTORC1_SIGNALING+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ANDROGEN_RESPONSE+0.300
- ANGIOGENESIS+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.300
- APICAL_SURFACE-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.100
- COMPLEMENT+0.000
- ESTROGEN_RESPONSE_EARLY+0.000
- ESTROGEN_RESPONSE_LATE+0.000
- FATTY_ACID_METABOLISM+0.000
- HEME_METABOLISM+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934967 | — | — | 0.863 |
| 2 | TCGA-FD-A6TH-01A-11R-A32O-07 | — | — | 0.844 |
| 3 | SRR12696801 | — | — | 0.833 |
| 4 | MNG544 | — | — | 0.827 |
| 5 | MNG296 | — | — | 0.813 |
| 6 | SRR12696793 | — | — | 0.809 |
| 7 | 5B474B14-FB1C-4B54-A9E8-3D652ADE6BA4 | — | — | 0.804 |
| 8 | SRR35579849 | — | E | 0.802 |
| 9 | E2C7E2B8-BC9B-476C-A705-CBBCA51F7C26 | — | — | 0.802 |
| 10 | 47757643-A7B2-4782-8DAF-AE56BE8777D2 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |